Korean J Med > Volume 89(1); 2015 > Article
소화기
The Korean Journal of Medicine 2015;89(1):35-42.
Published online July 1, 2015.
DOI: https://doi.org/10.3904/kjm.2015.89.1.35   
Receptor for Hepatitis B and D Virus
Kyun-Hwan Kim
Department of Pharmacology, Konkuk University School of Medicine, Seoul, Korea
B형 및 D형 간염바이러스 수용체
김균환
건국대학교 의학전문대학원 약리학교실
Correspondence: 
Kyun-Hwan Kim, Tel: +82-2-2030-7833, Fax: +82-2-2049-6192, Email: khkim10@kku.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Chronic hepatitis B affects 400 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. All clinically available hepatitis B virus (HBV) drugs are nucleoside or nucleotide analogs that inhibit viral reverse transcriptase (RT) activity. Resistance to these HBV drugs has been widely reported, and is due to specific mutations in the viral RT domain. Therefore, the development of new, non-polymerase targeting anti-HBV agents is urgently needed. A potential drug target, the HBV receptor that mediates the viral entry process, has been recently identified using human primary hepatocytes, northern tree shrew (Tupaia belangeri) hepatocytes, and HepaRG cells. A transporter of bile acids, sodium taurocholate cotransporting polypeptide (NTCP), was identified as the receptor for HBV and hepatitis D virus, and the transport function of NTCP was correlated with HBV entry. Therefore, functional inhibitors of NTCP may inhibit HBV infection, and viral entry was blocked by several NTCP receptor-targeting compounds. The HBV receptor is an attractive target for development of entry inhibitors, and serves as a model for the mechanistic study of HBV entry and infection. This review will summarize the characteristics and clinical importance of NTCP, and will discuss the potential therapeutic use of NTCP inhibitors to prevent HBV entry.
Key Words: Hepatitis B virus; Receptor; Sodium taurocholate cotransporting polypeptide
주제어: B형 간염 바이러스; 수용체; Sodium taurocholate cotransporting polypeptide


TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 3,612 View
  • 78 Download

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791    Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr                

Copyright © 2024 by The Korean Association of Internal Medicine.

Developed in M2PI

Close layer
prev next